Asterias Biotherapeutics Inc., of Fremont, Calif., said the data monitoring committee recommended continuation of enrollment in the SciStar phase I/IIa trial testing AST-OPC1 for acute spinal cord injury (SCI), with the 10 million and 20 million cell dose cohorts to continue as planned, following an interim review.